Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
暂无分享，去创建一个
D. Jäger | P. Ascierto | P. Sharma | P. Ott | C. Harbison | M. Pietanza | J. Bendell | M. Morse | J. Eder | J. López-Martín | R. Pillai | S. Antonia | I. Chau | E. Calvo | L. Horn | C. Pietanza | P. Bono | F. Braud | D. Le | Chen-Sheng Lin | A. Atmaca | F. de Braud | O. Christensen | J. Evans | A. Amin | J. Evans | Matthew H. Taylor